Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.48 |
| ▸ | SCN8A | Q9UQD0 | 6/20 | 0.47 |
| ▸ | SCN1A | P35498 | 5/20 | 0.47 |
| ▸ | PPIA | P62937 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL184154 | 0.94 | SCN8A (0.50) | SCN9ASCN5ASCN8ASCN1AKMT2A | |
| SCHEMBL184153 | 0.94 | SCN8A (0.50) | SCN9ASCN5ASCN8ASCN1AKMT2A | |
| SCHEMBL1603703 | 0.88 | SCN9A (0.49) | SCN9ASCN5ASCN8ASCN1AKMT2A | |
| SCHEMBL1603705 | 0.88 | SCN9A (0.49) | SCN9ASCN5ASCN8ASCN1AKMT2A | |
| SCHEMBL2626281 | 0.86 | KMT2A (0.52) | SCN9ASCN5ASCN8ASCN1AKMT2A | |
| SCHEMBL2625943 | 0.85 | KMT2A (0.47) | SCN9ASCN5ASCN8ASCN1AKMT2A | |
| SCHEMBL2626538 | 0.83 | SCN9A (0.49) | SCN9ASCN5ASCN8ASCN1AKMT2A | |
| SCHEMBL184272 | 0.83 | SCN9A (0.47) | SCN9ASCN5AKMT2A | |
| SCHEMBL184273 | 0.83 | SCN9A (0.47) | SCN9ASCN5AKMT2A | |
| SCHEMBL2625908 | 0.82 | KMT2A (0.55) | SCN9ASCN5ASCN8ASCN1AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097636-B2 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-17 | — | — | US | disclosed |
| US-20090124655-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124655-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, KCNN3 | SCN9A 125/4885SCN5A 60/4885SCN8A 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.